Arvind Sharma

Employment

• Moderna Therapeutics (United States) Associate Director
  2025 - Present
• Moderna Therapeutics (United States) Principal Scientist
  2024 - Present
• Moderna Senior Scientist
  2022 - 2024
• National Institute of Environmental Health Sciences Research Associate
  2022 - 2022
• Institut Pasteur Postdoctoral Fellow
  2016 - 2022
• International Centre For Genetic Engineering and Biotechnology New Delhi PhD student
  2009 - 2016

Education

• Guru Nanak Dev University Faculty of Life Sciences MSc (Masters of sciences)
  2006 - 2008
• DAV College Amritsar BSc (Bachelors of science)
  2003 - 2006

Projects & Funding

Projects & funding information is unavailable.

Publications (19)

• Cryo‐<scp>EM</scp> structures of engineered Shiga toxin‐based immunogens capable of eliciting neutralizing antibodies with therapeutic potential against hemolytic uremic syndrome
  Protein Science 2025 DOI: 10.1002/pro.70178
  +Save
• Modulation of SARS-CoV-2 spike binding to ACE2 through conformational selection
  Nature Nanotechnology 2025 DOI: 10.1038/s41565-025-01908-1
  +Save
• Modulation of SARS-CoV-2 spike binding to ACE2 through conformational selection
  2024 DOI: 10.1101/2024.03.15.585207
  +Save
• The epitope arrangement on flavivirus particles contributes to Mab C10’s extraordinary neutralization breadth across Zika and dengue viruses
  Cell 2021 DOI: 10.1016/j.cell.2021.11.010
  +Save
• Structural Principles of the Flavivirus Particle Organization and of Its Conformational Changes
  Reference Module in Life Sciences 2020 DOI: 10.1016/b978-0-12-814515-9.00102-8
  +Save
• Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis.
  Proceedings of the National Academy of Sciences of the United States of America 2019 DOI: 10.1073/pnas.1814685116
  +Save
• Covalently linked dengue virus envelope glycoprotein dimers reduce exposure of the immunodominant fusion loop epitope.
  2017 DOI: 10.1038/ncomms15411
  +Save
• Structure-based targeting of orthologous pathogen proteins accelerates anti-parasitic drug discovery.
  2017 DOI: 10.1021/acsinfecdis.6b00181
  +Save
• Structural basis of Zika virus neutralization by highly potent antibody
  Acta Crystallographica Section A Foundations and Advances 2017 DOI: 10.1107/s2053273317091859
  +Save
• Protein Translation Enzyme lysyl-tRNA Synthetase Presents a New Target for Drug Development against Causative Agents of Loiasis and Schistosomiasis
  PLOS neglected tropical diseases 2016
  +Save